U.S. Compounding Pharmacies Market Ecosystem, By Product Type, By Compounding Type, By Application (Pediatric, Adult, Geriatric, Veterinary), By Sterility, By Pharmacy Type, and By Therapeutic Area - Forecast to 2027

Analysis on U.S. Compounding Pharmacies Market – Ecosystem

This report evaluates “Global U.S. Compounding Pharmacies Market - Ecosystem” by studying Ecosystem analysis, trend intelligence and market revenue analysis. The compounding of medications is performed by pharmacists only if a specialized drug combination is needed for specific patients. The U.S. compounding pharmacies market - ecosystem was USD 4,861.4 Mn in the year 2019 and is expected to reach USD 7,304.46 Mn by the year 2027, growing at a CAGR of 5.2% during the forecast period. Compounding medications allow a physician to prescribe personalized medications prepared by a pharmacist for individuals.

In the U.S., around 56,000 community-based pharmacies are in operation, according to IACP. Apart from community-based pharmacies, there are around 7500 specialized compounding pharmacies, of which 3000 pharmacies make sterile products. The compounding program by the FDA ensures the availability of safe, effective, and lawfully marketed drugs to patients. Around 46 new medicines were approved by the U.S. FDA and Center for Drug Evaluation and Research (CDER) in the year 2017. The rise in the prevalence of chronic diseases in the U.S. also has a positive impact on the growth of the U.S. Compounding Pharmacies Market.

COVID-19 Impact Analysis & Opportunities in US Compounding Pharmacies Market

The outbreak of COVID-19 has bought along a global recession, which has impacted several industries. Along with this impact COVID Pandemic has also generated few new business opportunities for US Compounding Pharmacies industry. Overall competitive landscape and market dynamics of US Compounding Pharmacies has been disrupted due to this pandemic. All these disruptions and impacts has been analysed quantifiably in this report, which is backed by market trends, events and revenue shift analysis. COVID impact analysis also covers strategic adjustments for Tier 1, 2 and 3 players of US Compounding Pharmacies market.

Get a Free Sample Copy of the report at https://www.alltheresearch.com/sample-request/408

Ecosystem Snapshot of U.S. Compounding Pharmacies Market

U.S. Compounding Pharmacy Ecosystem

U.S. Compounding Pharmacies Market Segmentation

Product type

Compounding type



Pharmacy type

Therapeutic Area

Oral Medication

Pharmaceutical Ingredient Alteration



503 A

Hormone Replacement Therapy

Topical Medication

Currently Unavailable Pharmaceutical Manufacturing


Non- Sterile

503 B

Pain Management


Pharmaceutical Dosage Alteration





























On the basis of product type, the U.S. Compounding Pharmacies Market is categorized into oral medication, topical medication, mouthwashes, suppositories, and injectable. The oral medications segment dominated the market in 2019 with a share of 39.6% and is expected to account for a share of 40% in 2027. High demand for easy to administer dosage forms such as capsules, oral liquids, and granules will drive the growth of the segment. Rising health awareness and increasing demand for oral medication as the most preferred route of administration are projected to fuel the demand for oral medications over the forecast period.

In the Compounding type segment, the pharmaceutical ingredient alteration segment dominated the U.S. Compounding Pharmacies Marketing the year 2019 with a share of 35.6%. It is anticipated to grow with the highest CAGR of 5.9% over the forecast period.

In the U.S, the usage of compounding medication is higher among adults. This has resulted in the rapid growth of theU.S. Compounding Pharmacies Market, especially in the adult segment that was valued atUS$ 2,368.3Mn in the year 2019. The adult population in the United States demanded similar kinds of compounded medications, where medications for chronic pain therapies and hormone replacement therapies were the most preferred ones. On an average, the U.S. households spend USD 338 yearly on over the counter products. The majority of adult population in the United States use over the counter medicines as the first response to minor ailments.

The U.S. Compounding Pharmacies Market is categorized into 503A and 503B on the basis of pharmacy type. 503A has historically focused on compounding different topical cream products for pain management and on modifying the route of administration of other medications. 503As compounding pharmacies are not governed as strictly as 503Bs from a manufacturing viewpoint. 503Bs offer cheaper and more competitive alternatives to the conventional 503A model, allowing 503Bs to become a part of the hospital's drug supply chain. The 503B segment in the U.S. Compounding Pharmacies Market is expected to grow at a CAGR of 7.6% from 2019 to 2026. At present, only 73 FDA registered 503b facilities are present in the U.S.

On the basis of sterility, the U.S. Compounding Pharmacies market is segmented into Sterile and Non-sterile. Sterile compounding refers to the development of medications in an atmosphere that is free from bacteria, viruses, or any other infectious microorganisms. This kind of compounding is generally used for medications to be used through an IV injection or to be applied directly into the eyes of the patient. Administering medications through the aforementioned routes can pose the risk of developing infections, and thus, sterile compounding techniques help in reducing such risks significantly. The sterile segment is projected to witness an overall incremental growth of US$ 552.2 Mn between 2019 and 2027.

Non-sterile compounding involves creating medications in a clean environment, but it does not require the environment to be completely free from all microorganisms. These Non-sterile compounding medications can be consumed orally in the form of pills or as the liquid. In comparison to the medications that are injected, the risk involved in the oral ones is low. This factor contributes to the growth of the Non-sterile segment in the U.S. Compounding Pharmacies Market.

The Major Key Players operating in the U.S. Compounding Pharmacies market are as follows:


Ecosystem Positioning

Total Revenue 2018 (US$ Mn)


Fresenius Kabi

Product Manufacturer

$ 18,339.29 Million


Fagron NV

Product Manufacturer

$ 532.1Million


Clinigen Group

Product Manufacturer

$ 530Million


Central Admixture Pharmacy Services

Product Manufacturer

$ 257.1 Million


PharMEDium Services, LLC

Product Manufacturer

$ 209 Million


A Glance on U.S. Compounding Pharmacies Market Ecosyetm Key Trends:


Compounding Type

Short Term


Long Term

Dose alteration for adults according to individual needs is not available in the standardized doses manufactured by most pharma companies. This factor is driving the compounding pharmacies market.


Pharmaceutical Dose Alteration





High preference for compounded drugs among adult and geriatric age groups






An increase in bulk manufacturing by compounding pharmacies catering the hospital sector








Related Reports

Need specific market information ?

Ask for free product review call with the author

Share your specific research requirements for a customized report

Request for due diligence and consumer centric studies

Request for study updates, segment specific and country level reports

Ecosystem Report – Table of Content

  1. Introduction
    1. U.S. Compounding Pharmacies Market Definition
    2. Scope of study 
    3. Research Methodology
    4. Assumptions/Inferences
    5. Sources
      1. Primary Interviews
      2. Secondary Sources
        1. Key Secondary Webpages
        2. Whitepapers
        3. Annual Reports
        4. Investor/Analyst Presentations
    6. About FABRIC
  2. Executive Summary

Ecosystem Positioning

  1. U.S. Compounding Pharmacies Market Ecosystem Snapshot
    1. U.S. Compounding Pharmacies market segmentation
      1.  By Product Type
        1. Oral Medication
        2. Topical Medication
        3. Mouthwashes
        4. Suppositories
        5. Injectables
      2. By Compounding Type
        1. PIA
        2. CUPM
        3. PDA
        4. Others
      3. By Application
        1. Pediatric
        2. Adult
        3. Geriatric
        4. Veterinary
      4. By Sterility
        1. Sterile
        2. Non-Sterile
      5. By Pharmacy Type
        1. 503A
        2. 503B
      6. By Therapeutic Area
        1. Hormone Replacement Therapy
        2. Pain Management
        3. Dermatology
        4. Oncology
        5. Hematology
        6. Dental
        7. Others
    2. U.S. Compounding Pharmacies Market Ecosystem Broad Heads
  2. Competitive Landscape Mapping by Ecosystem Positioning
    1. A company by each node
    2. Vendor Landscaping
  3. Ecosystem Level Analysis

Trend Analysis

  1. U.S. Compounding Pharmacies market trends
    1. Short Term
      1. Trend Description
      2. Trend Evaluation
      3. Trend Outlook
      4. Trend Company Mapping
      5. Related U.S. Compounding Pharmacies market mapping
    2. Mid Term
      1. Trend Description
      2. Trend Evaluation
      3. Trend Outlook
      4. Trend Company Mapping
      5. Related U.S. Compounding Pharmacies Market Mapping
    3. Long Term
      1. Trend Description
      2. Trend Evaluation
      3. Trend Outlook
      4. Trend Company Mapping
      5. Related U.S. Compounding Pharmacies Market Mapping

U.S. Compounding Pharmacies Market Analysis

    1. Regulatory Analysis

U.S. Compounding Pharmacies Market Developments

    1. U.S. Compounding Pharmacies Market Events & Rationale
      1. R&D, Technology and Innovation
      2. Business & Corporate advancements
      3. M&A, JVs/Partnerships
      4.  Political, Macro-economic, Regulatory
      5.  Awards & Recognition
      6. Others

U.S. Compounding Pharmacies Market Sizing, Volume and ASP Analysis & Forecast

  1. U.S. Compounding Pharmacies Market Sizing & Volume
    1. Cross-segmentation
    2. U.S. Compounding Pharmacies Market Sizing and U.S. Compounding Pharmacies Market Forecast
    3. U.S. Compounding Pharmacies Market Volume Analysis
    4. Average Selling Price Analysis
    5. U.S. Compounding Pharmacies Market Growth Analysis

Competitive Intelligence

  1. Competitive Intelligence
    1. Top Industry Players vs Trend Tagging
        1. Importance
        2. Trend Nature (Positive/ Negative)
        3. Value
        4. Interconnectivity for each vendor
    2. U.S. Compounding Pharmacies Market Share Analysis
        1. By Each Node
    3. Strategies Adopted by U.S. Compounding Pharmacies Market participants
        1. U.S. Compounding Pharmacies Market Strategies
        2. New product launch Strategies
        3. Geographic Expansion Strategies
        4. Product-line Expansion Strategies
        5. Operational / Efficiency building Strategies
        6. Other Strategies

Company Profiles

  1. Company Profiles - including the:
      1. Central Admixture Pharmacy Services
      2. Company Fundamentals
      3. Subsidiaries list
      4. Share Holding Pattern
      5. Key Employees and Board of Directors
      6. Financial Analysis
        1. Financial Summary
        2. Ratio Analysis
        3. Valuation Metrics
      7. Product & Services
      8. Client & Strategies
      9. Ecosystem Presence
      10. SWOT
      11. Trends Mapping
      12. Analyst Views
    1. Fagron NV
    2. Advanved Pharma (Avella Specialty Pharmacy)
    3. SCA Pharma
    4. KRS Global Biotechnology Inc
    5. Fresenius Kabl Global
    6. PharMEDium Services, LLC
    7. Cantrell Drug Company
    8. Clinigen Group
    9. Smith Caldwell Drug Store
    10. Institutional Pharmacy Solutions
    11. Rx3 Compounding Pharmacy
    12. ITC Compounding Pharmacy
    13. Pentec Health
    14. McGuff Compounding Pharmacies Services, Inc.


  1. Ask for Customization
    1. Sensitivity Analysis
    2. TAM SAM SOM Analysis
    3. Other Customization
  2. Appendix
    1. Sources
    2. Assumptions
    3. Contact

Choose License

License Type
Ask for Customization

Why Choose AllTheResearch?

  • Monthly market updates for 6 months
  • Online access of reports
  • Options to buy sections of report
  • Critically analysed research on Quadrant Positioning of your company.
  • Syndicated report along with a supplementary report with objective-based study
  • Get profiled in the reports.Expanding your visibility across our network of readers and viewers
  • We provide local market data in local language on request
  • A complementary co-branded white paper
  • Flat consulting fee based exclusive studies. Consult at the price of syndicate
  • Access to expert team for free transaction advisory service.
Speak to Analyst

Quick Inquiry

Follow Us

Choose License

License Type
Ask for Customization